Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,309 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Otolaryngological Disease Clear all
Recruiting Phase 1Phase 2 Interventional

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

NCT04151082
View directory record Official record
Conditions
Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
Interventions
Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 4 Interventional

Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

NCT00636870
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

NCT00584987
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 12, 2026, 7:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Speech Perception and Amplification Benefit During Infancy

NCT05653999
View directory record Official record
Conditions
Hearing Loss, Children With Hearing Differences, Amplification, Speech Perception
Interventions
Hearing Aids
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 36 Months
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 12, 2026, 7:05 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
56
States / cities
Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Not applicable Interventional Results available

Osia CPT Code Study

NCT04320407
View directory record Official record
Conditions
Conductive Hearing Loss, Mixed Hearing Loss
Interventions
Osia 2 System
Device
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Community Health Navigators to Advance Cancer Screening Adherence

NCT06492993
View directory record Official record
Conditions
Cancer, Deafness
Interventions
Education
Other
Lead sponsor
Gallaudet University
Other
Eligibility
45 Years to 80 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Not applicable Interventional

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

NCT03418792
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy
Interventions
Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 12, 2026, 7:05 PM EDT
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 12, 2026, 7:05 PM EDT
Recruiting Not applicable Interventional

Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis

NCT06598319
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
NOVOCLEAR™ Device
Device
Lead sponsor
Aventix Medical Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Colorado Springs, Colorado • Ocean Springs, Mississippi • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC)

NCT00729781
View directory record Official record
Conditions
Nasal Alar Collapse, Bilateral
Interventions
Polyester Implants
Device
Lead sponsor
Medtronic Xomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Sacramento, California • Atlanta, Georgia • Downers Grove, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

NCT06633757
View directory record Official record
Conditions
Primary Ciliary Dyskinesia (PCD)
Interventions
RCT1100
Drug
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 3 Interventional

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

NCT00360100
View directory record Official record
Conditions
Otitis Media
Interventions
Zmax
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 48 Months
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Bardstown, Kentucky • Springfield, Kentucky
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children

NCT01044030
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Xylitol syrup, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 5 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 12, 2026, 7:05 PM EDT
Terminated No phase listed Observational

Patient Evaluation for Head and Neck Surgery Branch Studies

NCT00011492
View directory record Official record
Conditions
Head and Neck Neoplasms, Pharyngeal Cancer, Oral Cancer, Carcinoma, Squamous Cell, Laryngeal Cancer
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 12, 2026, 7:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

External Pharyngeal Exerciser and Pharyngeal Phase of Swallowing

NCT05708911
View directory record Official record
Conditions
Dysphagia
Interventions
Pharyngeal exerciser
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Not listed Phase 3 Interventional

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

NCT03472144
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions
gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 12, 2026, 7:05 PM EDT
Recruiting Phase 4 Interventional

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

NCT06665971
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

NCT03422536
View directory record Official record
Conditions
Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer, Oropharyngeal Cancer, HNSCC, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Interventions
Cetuximab, Ficlatuzumab
Biological · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • New Haven, Connecticut • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Irritation Study: Individual Factors in Nasal Irritant Sensitivity

NCT00041821
View directory record Official record
Conditions
Rhinitis, Allergic, Nonseasonal
Interventions
Nasal irritation thresholds and irritant provocation
Procedure
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Richmond, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Lansoprazole in Chronic Post Nasal Drip

NCT00335283
View directory record Official record
Conditions
Larynx Disease
Interventions
Lansoprazole Tablet, PH and impedence testing, manometry, lansoprazole, placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

NCT01633541
View directory record Official record
Conditions
Laryngeal Cancer
Interventions
AT-101, Docetaxel, Cisplatin, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 12, 2026, 7:05 PM EDT
Completed Phase 4 Interventional

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

NCT00235053
View directory record Official record
Conditions
Asthma, Candidiasis, Oral, Voice Disorders
Interventions
fluticasone/salmeterol DISKUS 250/50
Drug
Lead sponsor
Allergy & Asthma Medical Group & Research Center
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 12, 2026, 7:05 PM EDT